Arcturus touts $63M BARDA award for new mRNA influenza vaccine, hoping to prep against future pandemics
A San Diego mRNA biotech is looking to expand its efforts in influenza, and a federal award will bring it closer to that goal.
Arcturus Therapeutics said Wednesday that it won an award from HHS’s BARDA worth $63.2 million, a grant that was awarded as part of the entity’s pandemic influenza efforts. The grant will be divvied out over the next three years to boost Arcturus’ self-amplifying mRNA vaccine platform tech on multiple aspects, such as preclinical research, manufacturing, non-clinical safety studies and regulatory support.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.